// App-Quantinova.ai

EP644 : TEN-YEAR FOLLOW-UP OF 415 CLL PATIENTS TREATED WITH FLUDARABINE CYCLOPHOSPHAMIDE-BASED CHEMOIMMUNOTHERAPY IN THE FRONTLINE ARCTIC AND ADMIRE TRIALS, A COMPREHENSIVE ASSESSMENT OF PROGNOSTIC FACTORS

Researchers

Presenter

  • David Allsup

Principal Investigators

  • Zoe Criag

  • Dena Howard

  • David Cairns

  • Anna Hockaday

  • Adrian Bloor

  • Zarni Soe

  • Christopher Pepper

  • Schuh Anna

  • Tahla Munir

  • Andrew Rawstron

  • Peter Hillmen

Medical Centers

  • Cancer and pathology, St James University Hospital, Leeds, United Kingdom

  • St James Institute of Oncology, Leeds, United Kingdom

  • Clinical and Experimental Medicine,Brighton and Sussex Medical School,Brighton,Regno Unito

  • Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom

  • Department of Oncology, University of Oxford, Oxford, United Kingdom

  • Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom

  • Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved